

Urothelial Tract Cancer

Key Eligibility Criteria - Inclusion

- unresectable, locally adv or met UC (transitional cell and mixed transitional/non-transitional cell histologies in the renal pelvis, ureters, urinary urothelial, and urethra).
- **2L population:** previously treated with a platinum-based chemotherapy in the adv/met setting, progressed <12 mo NAC/Adj tx **OR** if >12 mo post-NAC/Adj but received one-line tx in adv/met setting
- **1L cisplatin-ineligible** : Progression >12 months after platinum-based neoadj or adj therapy and not received any prior systemic therapy in the adv/ met setting.
- Meet cis-ineligible criteria defined in the protocol and investigator opinion

Key Exclusion

- Prior anti-PD-1/PD-L1, anti-CTLA4 or anti-TIGIT antibody treatment excluded.
- Prior treatment with EV, SG or any other TROP2-targeted or deruxtecan-based ADCs excluded
- Active or prior documented autoimmune or inflammatory disorders

6A/B: 2L+, 1L Cis-inelig.
D-DXd + volrustomig or
rilvegostomig

Objective	Measure
Primary	Safety and ORR
Secondary	PFS, OS, DoR, DCR

*EV: Enfortuman vedotin

*SG: Sacituzumab govitecan